Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer

Alexandru Eniu, Frances M. Palmieri, Edith A. Perez

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Abstract

The taxanes docetaxel (Taxotere®; Avenus Pharmaceuticals Inc., Bridgewater, NJ, http://www.aventispharma-us.com) and paclitaxel (Taxol®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) have significant clinical activity in metastatic breast cancer. A number of clinical trials have evaluated the tolerability and efficacy of weekly taxane administration to optimize the benefit-to-risk ratio in metastatic breast cancer. Single-agent studies with docetaxel and paclitaxel in metastatic breast cancer show clinically significant antitumor activity even in advanced, heavily pretreated, resistant, and/or refractory disease. This activity is also evident with taxane-based combination regimens. Severe hematologic and nonhematologic toxicities are infrequent, with other toxicities noted based on the dose and weekly regimen selected. Weekly docetaxel and paclitaxel regimens represent valuable therapeutic options for women with metastatic breast cancer and have entered evaluation as part of adjuvant therapy for this disease.

Original languageEnglish (US)
Pages (from-to)665-685
Number of pages21
JournalOncologist
Volume10
Issue number9
DOIs
StatePublished - Oct 1 2005

Keywords

  • Breast cancer
  • Chemotherapy
  • Metastatic disease
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer'. Together they form a unique fingerprint.

Cite this